| # | Title | Journal | Year | Citations |
|---|
| 1 | VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis | BMC Musculoskeletal Disorders | 2007 | 134 |
| 2 | CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides | Journal of Rheumatology | 2016 | 66 |
| 3 | A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6‐mercaptopurine dosing in children with acute lymphoblastic leukemia | Pediatric Blood and Cancer | 2011 | 40 |
| 4 | Association of TNF-α polymorphisms in Crohn disease | Human Immunology | 2005 | 31 |
| 5 | High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis | Annals of the Rheumatic Diseases | 2011 | 19 |
| 6 | Teens Taking Charge: A Randomized Controlled Trial of a Web-Based Self-Management Program With Telephone Support for Adolescents With Juvenile Idiopathic Arthritis | Journal of Medical Internet Research | 2020 | 13 |
| 7 | CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitides – Executive Summary | Canadian Journal of Kidney Health and Disease | 2015 | 12 |
| 8 | Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial | BMJ Open | 2022 | 10 |
| 9 | Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire | Open Rheumatology Journal | 2015 | 7 |
| 10 | Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis | Rheumatology | 2023 | 6 |
| 11 | Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine | Expert Review of Precision Medicine and Drug Development | 2020 | 4 |
| 12 | Spinal mobility in radiographic axial spondyloarthritis: criterion concurrent validity of classic and novel measurements | BMC Musculoskeletal Disorders | 2021 | 3 |
| 13 | The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial | Advances in Therapy | 2022 | 3 |
| 14 | The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial | Advances in Therapy | 2022 | 2 |
| 15 | Probing for genes in seronegative spondyloarthropathy | Current Rheumatology Reports | 2000 | 1 |
| 16 | Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study | Annals of the Rheumatic Diseases | 2023 | 1 |
| 17 | The effect of ingestion of ferrous sulfate on the absorption of oral methotrexate in patients with rheumatoid arthritis | Journal of Rheumatology | 2003 | 0 |
| 18 | POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB | Annals of the Rheumatic Diseases | 2022 | 0 |
| 19 | POS1030 PAIN RESPONSE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB IS DRIVEN PREDOMINANTLY BY INFLAMMATION-INDEPENDENT EFFECTS | Annals of the Rheumatic Diseases | 2022 | 0 |
| 20 | POS1031 EARLIER CLINICAL RESPONSE PREDICT LOW RATES OF RADIOGRAPHIC PROGRESSION IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT | Annals of the Rheumatic Diseases | 2022 | 0 |
| 21 | POS1015 SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE BIO-NAÏVE OR TNFi-EXPERIENCED: POOLED RESULTS FROM 4 RANDOMIZED CLINICAL TRIALS THROUGH 2 YEARS | Annals of the Rheumatic Diseases | 2022 | 0 |
